Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)

NCT07700303 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

PROCEDURE: Discontinuation of parenteral prostacyclins analogues or selexipag

Sponsor

University of Alberta